Psyence Biomedical (PBMWW) Stock Price, News & Analysis

Company Overview

Psyence Biomedical plc is a clinical-stage biotechnology company focused on developing psychedelic-based medicines for mental health and other neurological conditions. The company’s programs are centered on psilocybin, a naturally occurring psychedelic compound, and are intended to support evidence-based therapeutic approaches in controlled clinical settings.

Psyence Biomedical’s lead development work includes PEX010, a proprietary psilocybin-based drug product being studied for potential use in conditions such as depression and adjustment disorder in patients receiving palliative care for cancer. The company’s research strategy combines psychedelic compounds with psychological support and psychotherapy, with the goal of addressing unmet needs in mental health care.

The company originated from Psyence Group, a life sciences organization established to develop natural psychedelic medicines, and became a publicly traded company through a business combination with Newcourt Acquisition Corp. in 2024. Psyence Biomedical is listed on Nasdaq under the symbol PBM, while PBMWW represents its publicly traded warrants. Its activities are primarily focused on advancing clinical development and potential commercialization through research and regulatory programs in relevant international markets.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.04
• 52-Week Range: $0.01 to $0.09
• Volume: 12,461 shs
• Average Volume: 42,769 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PBMWW
• CIK: 1985062
• Web: www.psyence.com
• Phone: 27744604171
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A